Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
boston blog main
boston top stories
indiana blog main
5
×
indiana top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
biotech
clinical trials
eli lilly
fda
sanofi
abbvie
congress
gene therapy
gilead sciences
glaxosmithkline
johnson & johnson
medicare
novartis
president trump
What
pharma
5
×
bio
drug
executives
roundup
abandoning
abbvie’s
administration
ago
ahead
angry
anti
away
baggage
benefited
biofourmis
biopharma
bringing
bucks
cancer
celebrate
ceos
chance
companies
congress
congressional
corner
crispr
cuts
day
days
dc
deal
despite
development
dicerna
fear
feud
forward
free
Language
unset
Current search:
photo
×
pharma
×
" indiana blog main "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M